39% of patients in the 50mg EFX group demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, a significant finding with a p-value of 0.009 compared to placebo. Data suggests ...
Mark W Begor, the CEO of $EFX, sold 1,402 shares of the company on 02-13-2025 for an estimated $359,344. We received data on the trade from a recent SEC filing. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback